Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook.
Latest Ratings for MRK
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | SVB Leerink | Maintains | Outperform | |
| Jan 2022 | JP Morgan | Maintains | Overweight | |
| Dec 2021 | Daiwa Capital | Initiates Coverage On | Neutral |
